MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil
FOSTER CITY, Calif., Sept. 22, 2023 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and the Fast Track Designation under the Generating Antibiotic Incentives Now (GAIN) Act for...
The UNICEF Charity Run 2023 Hosted Runners Calling Ceremony
Registration Closing Soon and Calling on Everyone to Run for Every Child! HONG KONG, Sept. 22, 2023 /PRNewswire/ -- UNICEF Charity Run 2023, the largest charity road race event in Hong Kong, will be held on the 5th of November this year at Hong Kong Disneyland Resort and Sunny Bay. A Runners Calling Ceremony for the event was held...
FDA Grants Fast Track Designation to 9MW3011
SHANGHAI, Sept. 22, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that FDA has granted Fast Track Designation (FTD) to 9MW3011 (R&D code in the US: MWTX-003/DISC-3405) for the treatment of patients with polycythemia vera (PV). Fast Track is a process to facilitate the development and expedite the review of drugs to treat...
BRACCO IMAGING S.p.A. ANNOUNCES GLOBAL AGREEMENT WITH SUBTLE MEDICAL, Inc.
Industry Leaders to Explore the Potential of AI in Contrast-Enhanced MRI MILAN, Sept. 21, 2023 /PRNewswire/ -- Bracco Imaging S.p.A., a global leader in diagnostic imaging, and Subtle Medical, Inc., a leading innovator in artificial intelligence (AI)-powered image acquisition, have entered into a global agreement in the field of magnetic resonance imaging (MRI)....
Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion function
SAN DIEGO, Sept. 21, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals (Inmagene), a clinical-stage biotech company developing innovative and differentiated therapies for immunological and inflammatory diseases, today announced its partnership with Aditum Bio to create Celexor Bio (Celexor), a new biotech company focused on cell depletion of pathologic cells in autoimmune and inflammatory disorders. Celexor has been formed based on Inmagene's IMG-018,...
Golidocitinib Granted Priority Review by China NMPA for the Treatment of r/r PTCL
SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- Dizal announced today that the China National Medical Products Administration (NMPA) has granted priority review status to golidocitinib, Dizal's investigational JAK1-only inhibitor, for the treatment of relapsed or refractory peripheral T-cell lymphoma (r/r PTCL). In February 2022, golidocitinib received Fast Track Designation from the U.S. Food...
VEDU Announces New Business Development and Management Team Changes
TORONTO, Sept. 21, 2023 /PRNewswire/ -- Visionary Education Technology Holdings Group Inc. (the "Company") (NASDAQ: VEDU), a private education provider located in Canada, with subsidiaries in Canada and market partners in China, today announced the Company has decided to diversify its business into three sectors: Education, Life Sciences, and Artificial Intelligence. In addition, the Board has appointed Mr....
AVANCE CLINICAL APPOINTS US-BASED EXECUTIVES – SVP SCIENTIFIC AND REGULATORY AFFAIRS, AND DIRECTOR BUSINESS DEVELOPMENT
ADELAIDE, Australia and RALEIGH, N.C., Sept. 21, 2023 /PRNewswire/ -- Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, announces two key appointments in the US to support its continued global growth. Avance Clinical's new appointments in the US: Kevin Leach & Madison Esely-Kohlman. Kevin Leach joins as Senior Vice...
New Wacom Signature Displays expand digital signature capture options for healthcare, financial services and transaction management
HONG KONG, Sept. 21, 2023 /PRNewswire/ -- Wacom announces its new Signature Displays the 13 touch (DTH134) and 12 (DTC121), a new eDocument solution enabling digital transformation initiatives. With an extremely simple, plug-and-play single cable connection, the Wacom Signature Displays enable an optimal user experience for digital document signing, form filling and annotation in any business application at hospitals, banks, insurance...
Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031
- The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacology, immunogenicity, and preliminary efficacy of ATG-031 in patients with advanced solid tumors or B-cell non-Hodgkin's lymphoma (B-NHL). - ATG-031,discovered and developed in-house by Antengene,is the world's first anti-CD24 antibody to advance to the clinic in oncology and Antengene's third drug candidate to enter clinical...
